Abbott Laboratories ABT
US equityMarket cap rank #93Medical DevicesBrain-Computer InterfaceInfectious DiseaseMpox (monkeypox)
$109.93 −$3.67 (-3.23%)
Market closed · Nov 6, 8:20 pm ET · Last extended-hours $109.93 0.00%
Open$111.08
Prev close$113.60
Day range$109.81 – $111.81
Volume8.35M
Market cap$190.39B
P/E (TTM)40.9
Dividend yield2.26%
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Institutional ownership81.1%+0.17 pts vs. prior quarter
Institutions holding3,422+40 vs. prior quarter
Insider trades (recent)36 buys / 12 sellsNet buying
Short interest1.00% of floatDays to cover 1.8 · as of 15 Oct 2026
Short-sale volume share18.8%5-day average of daily volume
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$149.95M (8 inflow days, 12 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 28.3% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 1.31% to 1.00% of float over the last 6 biweekly reports (31 Jul 2026 to 15 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +1,968,916 | 0.3% |
| Charles Schwab Investment Management | Mutual Fund | 2026/Q3 | +14,174,487 | 3.5% |
| BlackRock | Mutual Fund | 2026/Q3 | +6,876,018 | 8.8% |
| Citadel Advisors LLC | Hedge Fund | 2026/Q3 | +6,681,381 | 0.5% |
| Arrowstreet Capital, Limited Partnership | Mutual Fund | 2026/Q3 | +5,374,956 | 0.6% |
| SG Americas Securities, LLC | Private Company | 2026/Q3 | +4,736,848 | 0.4% |
| Barrow, Hanley, Mewhinney & Strauss, LLC | Mutual Fund | 2026/Q3 | +3,546,275 | 0.2% |
| Marshall Wace LLP | Hedge Fund | 2026/Q3 | +3,531,500 | 0.3% |
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +3,039,714 | 0.3% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +3,019,067 | 1.3% |
| Deutsche Asset & Wealth Management | Mutual Fund | 2026/Q3 | +2,664,096 | 0.9% |
| AQR Capital Management | Hedge Fund | 2026/Q3 | +2,612,790 | 0.2% |
| Flossbach von Storch SE | Mutual Fund | 2026/Q3 | +2,092,385 | 0.6% |
| The Goldman Sachs Group, Inc. | Public Company | 2026/Q3 | +2,006,794 | 0.4% |
| Strategic Advisers LLC | Mutual Fund | 2026/Q3 | +1,883,195 | 0.3% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 29 Sep 2026 | John Stratton | Independent Director | Other Derivative Acquisition | +397 | – | 14,499 |
| 29 Sep 2026 | Kevin Conroy | Director | Other Derivative Acquisition | +318 | – | 551 |
| 29 Sep 2026 | Michael Roman | Independent Director | Other Derivative Acquisition | +381 | – | 7,166 |
| 29 Sep 2026 | Patricia Gonzalez | Independent Director | Other Derivative Acquisition | +333 | – | 6,331 |
| 29 Sep 2026 | Nita Ahuja | Independent Director | Other Derivative Acquisition | +318 | – | 771 |
| 22 Sep 2026 | Kevin Conroy | Director | Sale to Issuer | -52,507 | $103.99 | 81,230 |
| 1 Sep 2026 | John McCoy | VP of Finance & Controller | Open Market Disposition | -27 | $109.54 | 24,608 |
| 31 Aug 2026 | John McCoy | VP of Finance & Controller | Sale to Issuer | -52 | $110.36 | 24,608 |
| 31 Aug 2026 | Philip Boudreau | CFO & Executive VP of Finance | Sale to Issuer | -388 | $110.36 | 82,316 |
| 24 Aug 2026 | Robert Ford | Executive Chairperson | Derivative Exercise and Sale | -398,832 | $116.19 | 522,664 |
| 11 Aug 2026 | Louis Morrone | Executive Vice President of Core Diagnostics | Disposition Under Employee Benef | -12 | $107.99 | 70,724 |
| 10 Aug 2026 | Louis Morrone | Executive Vice President of Core Diagnostics | Open Market Disposition | -5,850 | $109.83 | 70,724 |
| 29 Jun 2026 | John Stratton | Independent Director | Other Derivative Acquisition | +432 | – | 14,022 |
| 29 Jun 2026 | Kevin Conroy | Director | Other Derivative Acquisition | +231 | – | 231 |
| 29 Jun 2026 | Michael Roman | Independent Director | Other Derivative Acquisition | +416 | – | 6,746 |
| 29 Jun 2026 | Patricia Gonzalez | Independent Director | Other Derivative Acquisition | +363 | – | 5,963 |
| 29 Jun 2026 | Louis Morrone | Executive Vice President of Core Diagnostics | Sale to Issuer | -269 | $92.71 | 76,586 |
| 29 Jun 2026 | Nita Ahuja | Independent Director | Other Derivative Acquisition | +347 | – | 450 |
| 26 Jun 2026 | Elizabeth Cushman | General Counsel | Sale to Issuer | -560 | $94.12 | 38,013 |
| 14 May 2026 | Robert Alpern | Former Independent Director | Intent to Sell (Form 144) | -7,587 | $85.25 | – |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 17,386,736 | 1.0% | 1.8 |
| 30 Sep 2026 | 13,634,256 | 0.8% | 1.5 |
| 15 Sep 2026 | 19,911,199 | 1.2% | 2.6 |
| 31 Aug 2026 | 22,129,750 | 1.3% | 2.7 |
| 14 Aug 2026 | 20,375,133 | 1.2% | 2.9 |
| 31 Jul 2026 | 22,624,184 | 1.3% | 1.7 |
No comments yet — be the first to weigh in on ABT.
Sign in to join the discussion.